Teirstein, Paul S <br/><br/>
Impact of platelet glycoprotein IIb/IIIa Inhibition on the paclitaxel-eluting stent in patients with stable or unstable angina pectoris or provocable myocardial ischemia (a TAXUS IV substudy).  [electronic resource] 

 -  The American journal of cardiology  Aug 2005 
 - 500-5 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial 
<br/><br/><label>ISSN: </label>0002-9149 
<br/><br/><label>Standard No.: </label>10.1016/j.amjcard.2005.04.009  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Abciximab<br/>Angina, Unstable--blood<br/>Antibodies, Monoclonal--therapeutic use<br/>Antineoplastic Agents, Phytogenic--pharmacology<br/>Coated Materials, Biocompatible<br/>Coronary Angiography<br/>Coronary Restenosis--prevention & control<br/>Creatine Kinase--blood<br/>Creatine Kinase, MB Form<br/>Double-Blind Method<br/>Drug Interactions<br/>Eptifibatide<br/>Female<br/>Follow-Up Studies<br/>Humans<br/>Immunoglobulin Fab Fragments--therapeutic use<br/>Isoenzymes--blood<br/>Male<br/>Middle Aged<br/>Myocardial Ischemia--diagnostic imaging<br/>Myocardial Revascularization--instrumentation<br/>Paclitaxel--pharmacology<br/>Peptides--therapeutic use<br/>Platelet Aggregation Inhibitors--therapeutic use<br/>Platelet Glycoprotein GPIIb-IIIa Complex--antagonists & inhibitors<br/>Stents<br/>Tirofiban<br/>Treatment Outcome<br/>Tyrosine--analogs & derivatives